Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with a diagnosis of: Severe combined immunodeficiency disease~This includes patients whose SCID is characterized by gene specific mutations as well as patients with clinically severe combined immunodeficiency without a defined genetic cause in which the diagnosis will be determined by a combination of clinical course with lymphocyte quantification and function assays.~OR~Severe primary immunodeficiency disorder, including undefined T cell deficiency disorder, Wiskott-Aldrich syndrome, and other severe immunodeficiencies for which satisfactory conventional therapy does not exist.~* Availability of an HLA mismatched (up to one haplotype) family member or an HLA matched or mismatched (up to one antigen) unrelated donor.~* Creatinine \< 2.5 x normal for age.~* Life expectancy greater than 6 weeks~* Lansky/Karnofsky greater than or equal to 70%~Exclusion Criteria:~* Patients with an HLA matched related donor~* Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction less than 25%)~* Patients with known allergy to rat serum products~* Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation~* HIV positive~* Pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants With SCID or Primary Immunodeficiency Disorder (Type: EXPERIMENTAL): all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45

Based on this trial design, predict the completion outcome and termination type (if applicable).